All Eli Lilly articles – Page 2
-
Business
$25bn-plus trade sharpens pharma giants’ focus
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process
-
Business
Missing safety risk emails draw $9bn Actos fine
Judge finds absence of Takeda documentation in bladder cancer case ‘disturbing’
-
Business
Lilly wins cancer drug patent dispute
Alimta patent will last until 2022 after US court rules in Lilly’s favour
-
-
Business
Lilly freezes pay as patent cliff looms
Drugmaker targets $400 million savings as two key patents near expiry
-
Business
NHS to offer breast cancer prevention drugs
Five-year course of tamoxifen or raloxifene recommended for high risk women
-
Business
Patent woes lead to sharp sales losses
Bristol-Myers Squibb, AstraZeneca and Eli Lilly have all suffered loss of exclusivity for key drugs
-
Business
Alzheimer's drug flops in Phase III
Solanezumab from Eli Lilly missed the cognitive and functional primary endpoints of the trials
- Previous Page
- Page1
- Page2
- Next Page